Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Disc Medicine, Inc. - Common Stock (NQ:IRON)

60.03 -1.07 (-1.75%)
Streaming Delayed Price Updated: 3:54 PM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Disc Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2023 ↗
 
Via Benzinga
News headline image
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023 ↗
 
Via Benzinga
News headline image
Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter. 
Via Benzinga
News headline image
Ensysce Biosciences, AST SpaceMobile, IGM Biosciences And Other Big Stocks Moving Lower On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Why Heron Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
Gainers Bird Global, Inc. (NYSE: BRDS) shares rose 58.7% to $0.2250 in pre-market trading after gaining more than 17% on Thursday. Bird announced plans to expand across Greater Toronto area this... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023 ↗
 
Via Benzinga
News headline image
Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)
IND accepted for phase 2 clinical trial in DBA patients; study is expected to initiate mid-year 2023 
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Opco Inc (NASDAQ: IRON) Investor Notice: Investigation over Possible Securities Laws Violations ↗
San Diego, CA -- (SBWIRE) -- 03/20/2023 -- An investigation was announced for investors of Disc Medicine Opco Inc (NASDAQ: IRON) shares over potential securities laws violations in connection with... 
Via SBWire
News headline image
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement ↗
Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had... 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023 ↗
 
Via Benzinga
News headline image
$2M Bet On PayPal? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
News headline image
Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine to Participate in SVB Securities Global Biopharma Conference
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million ↗
Mabwell Biosciences out-licensed global rights for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Mabwell will receive $10 million upfront, $402.5 million in... 
Via Talk Markets
News headline image
Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis
From Disc Medicine Inc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023 ↗
 
Via Benzinga
News headline image
Stocks Stumbling Out Of 2023's Gate ↗
Stocks were unable to fulfill premarket gains, as two familiar foes -- rising rates and high inflation -- dampen investor sentiment to start the new trading year. 
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>